Comparative evaluation of the application of hepatoprotector LIV-52 and prebiotic Rekicen-RD in preventive correction of experimental NSAID-hepatopathywith Nimesulide
https://doi.org/10.31146/1682-8658-ecg-176-4-115-120
Abstract
Objective: to conduct a comparative assessment of the use of the hepatoprotector and the prebiotic in NSAIDs-hepatopathy, induced by prolonged use of nimesulide using histological and immunohistochemical methods.
Materials and methods: The experiment was conducted on laboratory animals (rats), which were used to model NSAID-hepatopathy by administering nimesulide by the oral route for 21 days. Animals from the two experimental groups received a hepatoprotector and a prebiotic (simultaneously with nimesulide). The eff ect of the drugs was assessed by the results of histological examination of the liver tissue and the manifestation of the immunohistochemical expression of receptors of tumor necrosis factor α (TNFαR1) on hepatocytes. To detect receptor expression, labeled TNFR1 (polyclone) antibodies, species-specifi c to rat tissue antigens, were used.
Results: histological examination of animals from experimental groups revealed the preservation of liver tissue, which was manifested by a decrease in pathological disorders. The study of immune responses in the pathogenesis of NSAIDs-hepatopathy demonstrated that the simultaneous use of both hepatoprotector and prebiotic signifi cantly reduced the eff ect of tumor necrosis factor α on liver tissue, which was confi rmed by a low level of TNFαR1 expression in animals of experimental groups compared to manifestations of TNFαR1 expression in animals with NSAID-hepatopathy. Hepatoprotector had a more pronounced protective eff ect compared to the prebiotic.
Conclusion: studies have shown that the simultaneous use of both hepatoprotector and prebiotic with nimesulide reduces histomorphological and immune disorders in the liver tissue. Drugs can be recommended for the correction of pathological disorders of the liver tissue with prolonged use of NSAIDs.
About the Authors
L. V. Lazarenko
Perm Institute of the Federal Penal Service
Russian Federation
Associate Professor of the Department of Zootechnics, Candidate of Veterinary Sciences
125, Karpinski str., Perm, Russia, 614012
Russian Federation
Associate Professor of the Department of Zootechnics, Candidate of Veterinary Sciences
125, Karpinski str., Perm, Russia, 614012
P. V. Kosareva
Perm State National Research University
Russian Federation
Professor of the Department of Inorganic Chemistry, Chemical Technology and Technosphere Safety, Doctor of Medical Sciences
15, Bukireva str., Perm, Russia, 614990
Russian Federation
Professor of the Department of Inorganic Chemistry, Chemical Technology and Technosphere Safety, Doctor of Medical Sciences
15, Bukireva str., Perm, Russia, 614990
References
1. Lazebnik L. B., Golovanova E. V., Alekseenko S. A. et al. Recommendations for the prevention and treatment of esophago-gastro-entero-colopathy induced by nonsteroidal antiinflammatory drugs “nsaid”. Experimental and Clinical Gastroenterology. 2018;151(03):04–18.
2. Zholobova E. S., Konopelko O. Yu., Gesheva Z. V. Gepatotoksichnost nesteroidnyih protivovospalitelnyih preparatov, primenyaemyih v detskoy revmatologii [Hepatotoxicity of non-steroid anti-inf lammatory drugs used in child rheumatology]. Pediatrics. 2009; 88(5):155–160.
3. Walker A. M. Quantitative studies of the risk of serious hepatic injury in persons using nonsteroidal antiinflammatory drugs. Arthritis Rheum. 1997;40:201–208.
4. Greaves R. R. Agarwal A., Patch D. et al. Inadvertent diclofenac rechallenge from generic and non-generic prescribing, leading to liver transplantation for fulminant liver failure. Eur. J. Gastroenterol. Hepatol. 2001;13:71–73.
5. O’Connor N., Dargan P. I., Jones A. L. Hepatocellular damage from non-steroidal anti-infl ammatory drugs. Q. J. Med. 2003;96:787–791.
6. Polunina T. E., Maev I. V. Lekarstvennye porazheniya pecheni [Drug-induced liver injury]. Consilium medicum. Gastroenterology. 2011;2:54–60.
7. Antonenko O. M. Toksicheskie porazheniya pecheni: puti farmakologicheskoj korrekcii [Hepatotoxicity: options for pharmacological correction]. Medical Council. 2013;6:45–51.
8. Aksenova V. A., Protopopova G. R., Madasova V. G. et al. Primenenie LIV-52 v profi laktike nezhelatelnyih gepatotoksicheskih reakcij pri himioterapii tuberkuleza u detej i podrostkov [The use of LIV-52 in the prevention of undesirable hepatotoxic reactions in chemotherapy of tuberculosis in children and adolescents]. Hospital. 2003;5:10–11.
9. Uchajkin B. F., Cherednichenko T. V., Chaplygina G. V., Pisarev A. G. Liv. 52 – novyj vzglyad na effektivnost pri ostryh i xronicheskih virusnyih gepatitax u detej [Liv.52 in a new view on the effectiveness of acute and chronic viral hepatitis in children]. Children’s Infections. 2003;3:41–45.
10. Babayan M. L., Volynecz G. V. Opyt primeneniya Liv.52 v pediatricheskoj praktike (Obzor literatury) [Experience in the application of Liv.52 in pediatric practice (literature Review)]. Russian Medical Journal. Pediatric gastroenterology. 2004;(12)3:135–141.
11. Kozlova I. V., Lipatova T. E., Afonina N. G., Kvetnoj I. M. NSAID-induced gastropathy in osteoarthrosis patients: role of stomach diffuse endocrine system factors in its development. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2006;(16)1:47–53.
12. Kogan E. A., Nizyaeva N. V., Demura T. A. et al. Autonomy of growth foci of adenomyosis: immunohistochemical particular expression of markers. Medline.ru. Immunology. 2011;(12)1:311–325.
13. Lazarenko L. V., Kosareva P. V., Samodelkin E. I, Horinko V. P. Experimental NSAIDs-induced hepatopathy caused by long use of nimesulide. Perm medical journal. 2015;(32)3:120–124.
14. Lazarenko L. V., Kosareva P. V., Samodelkin E.I, Horinko V. P. Tumor necrosis factor in the pathogenesis of NSAID-associated hepatopathy. Journal of Anatomy and Histopathology. 2017;6(3):50–55. https://doi.org/10.18499/2225–7357–2017–6–3–50–55
15. Enescu A., Mitrut P., Buteica E. et al. Drug-induced hepatitis – morphological and ultrastructural aspects. Romanian Journal of Morphology and Embryology. 2007;48(4):449–454.
16. Baranovskij A. Yu., Marchenko N. V., Mitelglik U. A., Rajxelson K. L. The role of alpha tumor necrosis factor in the development of autoimmune liver disease: recurring problem. Practical medicine. 2014;1:15–19.
17. Dandagi P.M., Patil M. B., Mastiholimath V. S. et al. Development and Evaluation of Hepatoprotective Polyherbal Formulation Containing Some Indigenous Medicinal Plants. Indian J Pharm Sci. 2008;70(2):265–268.
18. Sisodia S.S., Bhatnagar M. Hepatoprotective activity of Eugenia jambolana Lam. in carbon tetrachloride treated rats. Indian J Pharmacol. 2009;41(1):23–27.
19. Roy A., Soni G. R., Kolhapure R. M. et al. Down regulation of tumour necrosis factor activity in experimental hepatitis by a herbal formulation, Liv-52. Indian J Exp Biol. 1994;32:694–697.
20. Kobayashi M., Mikami D., Kimura H. et al. Shortchain fatty acids, GPR41 and GPR43 ligands, inhibit TNF-α-induced MCP-1 expression by modulating p38 and JNK signaling pathways in human renal cortical epithelial cells. Biochemical and Biophysical Research Communications. 2017;2:499–505. http://dx.doi.org/10.1016/j.bbrc.2017.03.071
21. Vinolo M.A., Rodrigues H. G., Hatanaka E. et al. Suppressive effect of short-chain fatty acids on production of proinfl ammatory mediators by neutrophils. J Nutr Biochem. 2011;9:849–855. https://doi.org/10.1016/j.jnutbio.2010.07.009
Review
For citations:
Lazarenko L.V., Kosareva P.V. Comparative evaluation of the application of hepatoprotector LIV-52 and prebiotic Rekicen-RD in preventive correction of experimental NSAID-hepatopathywith Nimesulide. Experimental and Clinical Gastroenterology. 2020;174(4):115-120. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-176-4-115-120
Views:
872
Email this article 